Drug intelligence / Profile preview

CRB1401

Development stage: Unknown
Lead developer: China Resources Pharmaceutical Holdings
Modality: Recombinant Proteins and Enzymes
Administration: Parenteral, Intravenous, Subcutaneous

Overview

CRB1401 is a recombinant protein therapeutic being developed by China Resources Biopharmaceutical (and its subsidiary China Resources Angde Biopharmaceutical) for the treatment of cardio-cerebrovascular diseases. As a biologic candidate, it is designed to target underlying pathological mechanisms in cardiovascular and cerebrovascular conditions. CRB1401 has successfully completed Phase I clinical evaluation in China and is currently in Phase II clinical development.

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on CRB1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRB1401.

Explore the full profile